Paris, France, 02 June, 2025 — From May 20 to 23, MicroPort® participated in EuroPCR 2025 in Paris, showcasing a comprehensive range of innovations in coronary intervention, structural heart disease, and extracorporeal life support (ECLS). The company highlighted its integrated solutions to thousands of global experts.
On May 22, MicroPort® presented the one-year results of CORECT clinical trial. The trial confirmed the safety and efficacy of FireRaptor®, a novel rotational atherectomy system designed to address the challenges of complex, calcified coronary lesions. The study demonstrated a 97.3% 30-day MACE-free rate, successfully meeting the non-inferiority endpoint (P<0.0001) compared to the control group. FireRaptor® also delivered strong and consistent results across key procedural metrics with device success of 97.3% vs 99.1% (P=0.3672), angiographic success of 96.3% vs 99.1% (P=0.2082), and clinical success of 94.5% vs 96.4% (P=0.5364). With comparable outcomes to established systems and a streamlined, operator-friendly design, FireRaptor® provides an effective and accessible solution for broader clinical adoption, bringing efficiency and confidence to complex PCI.
At EuroPCR 2025, MicroPort® also showcased its flagship products, including Firesorb®, Firehawk®, Firehawk™ Liberty, Firefighter™, Firefighter™ NC, VitaFlow® Liberty, Anchorman®, and MOBYBOX™. By integrating innovation and collaboration, MicroPort® reaffirms its commitment to advancing cardiovascular care and improving lives worldwide.
About MicroPort®
Founded in 1998 on the belief that every person has the right to high quality medical treatments, MicroPort® (MicroPort Scientific Corporation; HKEX: 00853) is a global medical devices company. MicroPort® provides solutions across twelve therapeutic areas, including cardiovascular, orthopedics, cardiac rhythm management, electrophysiology, endovascular, neurovascular and surgical robotics among others. For over 27 years, MicroPort® has been breaking barriers and accelerating access to life-changing solutions so that patients everywhere can continue living better and longer lives. With therapeutic solutions that are available in more than 100 countries and over 20,000 hospitals around the world, today, every 5 seconds or less, a patient around the world benefits from a MicroPort® life-changing solution.
More information is available at: www.microport.com